Prescribing outcomes for HR+ early breast cancer in England (PELTA)

• Research type

  Research Database

• IRAS ID

  268204

• Contact name

  MHR Chowdhury

• Contact email

  Ruhe.Chowdhury@pfizer.com

• Research summary

  PELTA

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  19/SC/0414

• Date of REC Opinion

  6 Nov 2019

• REC opinion

  Further Information Favourable Opinion

• Data collection arrangements

  This datase will hold de-identified patient-level data for patients diagnosed with hormone receptor positive early-stage breast cancer in England from 1st January 2014 up until 31st December 2017. The data will be sourced retrospectively from a pre-existing healthcare database held at Public Health England, a research arm of the Department of Health in England. Data collection will have occurred independently by Public Health England who will determine all arrangements for the collection, formatting and transfer of data; Pfizer will have no involvement in this initial process and Public Health England will have pre-approved the location of data storage.

• Research programme

  The database will facilitate analyses of real-world prescribing practices, patients’ characteristics, clinical outcomes and healthcare resource utilisation for the treatment of early-stage hormone receptor positive breast cancer in England.

• Research database title

  PELTA

• Establishment organisation

  Pfizer Ltd

• Establishment organisation address

  Dorking Road

  Tadworth

  KT207NS